PREDQ (Predictive Technology Group) Ending Cash Position: $0.15 Mil (As of Mar. 2021)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Predictive Technology Group Ending Cash Position?

Predictive Technology Group PREDQ -90.00% Ending Cash Position is $0.15 Mil as of Mar. 2021.

Predictive Technology Group's Ending Cash Position for the quarter that ended in Mar. 2021 was $0.15 Mil.

Predictive Technology Group's quarterly Ending Cash Position declined from Sep. 2020 ($1.27 Mil) to Dec. 2020 ($0.13 Mil) but then increased from Dec. 2020 ($0.13 Mil) to Mar. 2021 ($0.15 Mil).

Predictive Technology Group's annual Ending Cash Position increased from Jun. 2018 ($1.21 Mil) to Jun. 2019 ($1.62 Mil) but then declined from Jun. 2019 ($1.62 Mil) to Jun. 2020 ($0.33 Mil).

Predictive Technology Group Ending Cash Position Related Terms

Predictive Technology Group Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Predictive Technology Group's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Predictive Technology Group Ending Cash Position Chart

Predictive Technology Group Annual Data
Trend Aug06 Aug07 Jun16 Jun17 Jun18 Jun19 Jun20
Ending Cash Position
Get a 7-Day Free Trial 0.01 0.97 1.21 1.62 0.33

Predictive Technology Group Quarterly Data
Nov07 Feb08 May08 Jun16 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.33 1.27 0.13 0.15

Predictive Technology Group Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Predictive Technology Group's Ending Cash Position for the fiscal year that ended in Jun. 2020 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1.618+-1.287
=0.33

Predictive Technology Group's Ending Cash Position for the quarter that ended in Mar. 2021 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.135+0.017
=0.15

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.15 Mil mean?
Predictive Technology Group (PREDQ) has a Ending Cash Position of $0.15 Mil as of Mar. 2021. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Predictive Technology Group and its competitors.
Is Predictive Technology Group's Ending Cash Position too high?
Predictive Technology Group's current Ending Cash Position is $0.15 Mil.
How does Predictive Technology Group's Ending Cash Position compare to GLMD and RCAR?
Predictive Technology Group's Ending Cash Position of $0.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Predictive Technology Group and its competitors. Predictive Technology Group's current Ending Cash Position is $0.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Predictive Technology Group stock overvalued right now?
Predictive Technology Group (PREDQ) has a current Ending Cash Position of $0.15 Mil. The current Ending Cash Position is $0.15 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Predictive Technology Group (PREDQ), the current Ending Cash Position is $0.15 Mil as of Mar. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Predictive Technology Group Business Description

Address 2735 Parleys Way, Suite 205, Salt Lake City, UT, USA, 84109
Predictive Technology Group Inc (PRx) is a biotechnology company. It develops, commercializes, acquires and invests in technologies engaged in novel molecular diagnostic and therapeutic products in healthcare. The HCT/P segment offers minimally manipulated tissue products intended for homologous use, prepared utilizing proprietary extraction methods that reduce the loss of important scaffolding, growth factors and cytokines. The company's Diagnostics and Therapeutics segment uses data analytics for disease identification and subsequent therapeutic intervention through novel gene-based diagnostics, and companion therapeutics. It generates most of its revenues from HCT/Ps segment.